The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 04, 2025
Filed:
Feb. 25, 2019
The Australian National University, Acton, AU;
Griffith University, Nathan, AU;
Christopher Parish, Kingston, AU;
Connor O'Meara, Newcastle, AU;
Lucy Coupland, Chifley, AU;
Benjamin Ju Chye Quah, Jerrabomberra, AU;
Farzaneh Kordbacheh, Belconnen, AU;
Anna Orlov, Narrabundah, AU;
Anna Browne, Acton, AU;
Ross Stephens, Stirling, AU;
Gregory David Tredwell, Turner, AU;
Lee Andrew Philip, Greenleigh, AU;
Karen Knox, Ellen Grove, AU;
Laurence Mark von Itzstein, Gilston, AU;
Chih-Wei Chang, Upper Commera, AU;
Anne Bruestle, Acton, AU;
David Anak Simon Davis, Belconnen, AU;
The Australian National University, Acton, AU;
Griffith University, Nathan, AU;
Abstract
The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of NET mediated ailments in subjects.